Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Phase 4
N/A
N/A
N/A
N/A
Open (Enrolling by invite only)
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
All cases at the participating institutions.
Inclusion Criteria:
- Postmenopausal women with breast cancer eligible for hormonal therapy.
Exclusion Criteria:
- Pregnant breast-feeding premenopausal.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and causality will be monitored in this study.
Outcome Time Frame:
adjuvant 1 year ; advanced 6 years
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Korea: Food and Drug Administration
Study ID:
A5991089
NCT ID:
NCT01047358
Start Date:
August 2010
Completion Date:
July 2014
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
